CorVel Corp. (CRVL) earned $0.67 per share in its fiscal second quarter ended September 2026, up 24.1% from a year ago, on revenue of $267.13 million, up 11.5%. No consensus estimate or Earnings Whisper was available, so the quarter has to be judged on its own trajectory. On that basis it was strong. Revenue growth held at the double-digit pace reached last quarter, but profit growth ran at more than twice that rate. The story has shifted from a top-line recovery to one of operating leverage.

The income statement supports that reading. Gross profit rose 24% to $72.3 million, and gross margin widened to 27% from 24% a year earlier and from 23.3% as recently as the December 2025 quarter. General and administrative expense grew about 19%, slower than gross profit, so operating income climbed roughly 28% to $45.8 million. Operating margin expanded from about 15% to just over 17%. Net income rose a more modest 22% because the effective tax rate increased to roughly 25.6% from about 22% a year ago. A diluted share count about 2% lower helped close the gap to the 24.1% EPS gain. The sequential picture is cleaner than it first appears. The prior quarter's $0.63 included about $0.07 from a one-time CERIS receivables settlement, so underlying earnings stepped up meaningfully from roughly $0.56 to $0.67.

The call analysis shows a demand engine that is still gaining speed even though headline growth has leveled off. Year-over-year revenue growth has run 3%, 7%, 11% and now 11% over the past four quarters, and trailing twelve-month revenue passed $1 billion. Underneath that plateau, claims volume growth accelerated to 11.5% from 8% in the prior quarter. Sales closures more than doubled year over year, following a 60% gain in new sales last quarter and 56% bookings growth the quarter before. That pipeline suggests revenue growth has not peaked. Management also changed how it frames artificial intelligence. Earlier calls presented AI as a prospective benefit. Management now ties AI-assisted claim summarization and workflow automation directly to operating leverage and better margins. Days sales outstanding improved to 37 from 39 in the prior quarter.

CERIS, the payment-integrity business, delivered the most notable new catalysts. It implemented another top-10 national health plan, signed a strategic partnership that opens access to the Blue Cross Blue Shield market, and introduced Hospital Bill Audit and Professional Claims prepayment products. Marketwise Repricing for out-of-network bills, an expanded pharmacy benefits program and the MyCare self-service portal broaden the managed-care offering. The risks are real, if less dramatic:

• **Capacity strain:** Claims volume growing faster than revenue raises the question of whether service quality and staffing can keep pace.
• **Slower buybacks:** Repurchases fell to $18.1 million from $21.8 million in the prior quarter and $20 million the quarter before.
• **Limited visibility:** The company again offered no formal guidance and took no analyst questions.

There is a disclosure discrepancy worth noting. The call analysis flags cash and free cash flow as missing from the transcript, but the press release reports $270 million in cash and no borrowings, up from $233 million in March. Customer deposits of $130 million are part of that cash position. Free cash flow was not disclosed in either source.

Market context is sparse this cycle. Investor sentiment readings, a current share price and inter-earnings range data were not available. Shares opened at $59.06 after the August report, below the current 200-day moving average of $62.65. That suggests the stock entered this period trading under its longer-term trend even as fundamentals improved, though whether it has since recovered that level cannot be determined from the supplied data. The absence of guidance and analyst Q&A means the market must rely on reported trends rather than management targets. That favors a company producing consistent results, but it can amplify reactions to any stumble.

The bottom line is that CorVel's quarter was better than its steady 11.5% revenue growth implies. Gross margin up three points, operating income up roughly 28%, and accelerating claims volume and sales closures point to a business converting growth into profit more efficiently than it was a year ago. Bears can point to the revenue-growth plateau, slower buybacks, a higher tax rate and a near-total lack of forward commentary. Still, the sales pipeline and CERIS expansion give the growth story credible support, and margin leverage is now the variable to watch.